NSW records 1,180 peptide-linked emergency visits amid warnings on online products

The NSW surveillance figures show monthly presentations rising from five in July 2025 to more than 217 in September 2026. The state is urging people to use peptide products only when prescribed by a GP and obtained from a pharmacy. In an ABC News interview, a NSW minister described liver damage, kidney damage, severe allergic reactions and vomiting among the problems seen, and warned that unregulated products could cause irreversible organ damage.⁠2⁠1

Those numbers are serious without being stretched. They count visits, not an established number of different people, and they are not a tally of hospital admissions. The surveillance describes presentations as “associated with peptide use”; that does not establish that a peptide caused every illness. Nor does the total tell us how many people suffered lasting injury.⁠2

The central problem is not that every peptide medicine is dangerous. Australia's Therapeutic Goods Administration distinguishes approved peptide products from the many unapproved products promoted online, which may be unlawful. Collapsing those categories would obscure the warning: an online promise of recovery or rejuvenation is no substitute for an assessed medicine and a trustworthy supply.⁠12

The written NSW release supplies a precise reporting window: 1 July 2025 to 30 September 2026. Its 1,180 presentations are the cumulative total across those fifteen months, not September's total. For September itself, the official wording is “more than 217”—a threshold, not an exact count of 217.⁠2

That precision also matters at the beginning of the series. In the ABC News interview published on 18 October 2026, the minister described a handful of presentations in June 2025 and close to 1,200 over a little more than twelve months. The written NSW surveillance release gives the more precise total and dates, beginning with five presentations in July 2025. June is an earlier observation, outside that reporting window; it should not be relabelled as July's baseline or folded into the fifteen-month total.⁠1⁠2

Both accounts describe a sharp increase. But the clean, dated comparison is five presentations in July 2025 against more than 217 in September 2026. The available figures do not explain how presentations were classified, whether some people attended repeatedly, or which products accounted for the increase.⁠2

The clinical warning must be read with similar care. The minister's description of liver and kidney damage, severe allergic reactions and vomiting identifies potentially serious problems requiring emergency care. The warning about irreversible organ damage describes a possible consequence—not a finding that every presentation involved permanent damage. No numerical breakdown of those problems, recoveries or lasting injuries accompanies the figures.⁠1⁠2

The NSW warning names BPC-157, GHK-Cu, TB-500, retatrutide and CJC-1295 as substances products may claim to contain. That wording is important. It identifies marketing claims, not verified ingredients, and it does not show that each named substance was used by patients in the surveillance count or caused their symptoms.⁠2

The products are marketed through social media with purported wellness benefits, including weight loss, injury repair and reversing ageing. The minister warned that unregulated products may contain something different from what buyers expect or what has been prescribed. Before any claimed benefit can be weighed, there is a more basic question: is the product what its seller says it is?⁠2⁠1

Federal purchasing advice published on 18 May 2026 recommends trusted sources, such as an Australian registered pharmacy. Products not approved for Australian supply have not been assessed by the TGA for safety, quality and effectiveness. A prescription alone is not proof of Australian product approval; prescribing and product approval are different questions.⁠16⁠24

Nor does the existence of the Personal Importation Scheme make a particular purchase safe or establish that it is lawful. The TGA's 7 May warning specifically addressed risks from imported unapproved peptides, including products entering through that scheme. The available official material does not establish the access conditions or approval status of every formulation named in the NSW warning. It would be wrong to turn that gap into either a blanket declaration of illegality or a reassurance.⁠14⁠12⁠2

The national response began well before the NSW figures emerged. A TGA alert displayed as published on 13 April 2026 addressed importing, compounding, supplying and advertising unapproved peptide products. After its May import warning, the regulator expanded its compliance focus on 10 June following increased detection of unlawful importation, supply and advertising. A joint statement with the Chief Medical Officer followed on 19 June.⁠13⁠14⁠15⁠5

On 14 September, the TGA issued a more specific instruction: products marketed as retatrutide for weight loss may pose a serious health risk and should not be used. Its general peptide information page, updated on 23 September, continued to distinguish approved products from unapproved products promoted online. These were targeted warnings, not a rejection of every medicine containing a peptide.⁠23⁠12

The missing detail limits what can be concluded about individual substances. It does not make the hospital figures trivial. NSW has recorded more than 217 associated emergency visits in one month while warning that buyers of unapproved products may be taking something different from what the label promises. That is the gap the wellness marketing cannot answer.⁠2⁠1